Form 4: Century Therapeutics SVP Douglas Carr Reports Stock and Option Awards

Douglas Carr, SVP of Finance & Operations at Century Therapeutics, reports the acquisition of 14,000 shares of common stock and options to purchase 81,000 shares.

Summary

• Douglas Carr, SVP of Finance & Operations at Century Therapeutics, filed a Form 4 on March 11, 2024.
• The filing reports a transaction date of March 7, 2024.
• Carr acquired 14,000 shares of common stock and options to purchase 81,000 shares.
• The common stock was acquired at a price of $0.
• The option has an exercise price of $5.32 and expires on March 7, 2034.
• Following the reported transactions, Carr beneficially owns 317,580 shares of common stock and options to purchase 81,000 shares.
• The filing also includes a Power of Attorney, granting Brent Pfeiffenberger and Gregory Russotti the authority to execute Forms 3, 4, and 5 on Carr's behalf.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option grants, which are typical compensation components. There's no indication of unusual or concerning activity.

Positives

• The acquisition of shares and options by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting schedules for the RSUs and options suggest a long-term commitment from the executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices for executives in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants and RSU awards are common compensation components for executives in publicly traded biotechnology companies.
• Vesting schedules, such as the one described (25% after one year, then quarterly or monthly), are typical for incentivizing long-term performance and retention.
• Comparable companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize stock options and RSUs in their executive compensation packages.

Stakeholder Impact

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders, incentivizing long-term value creation.

Key Dates